Search hospitals > Maine > Scarborough
Maine Medical Center- Scarborough Campus
Claim this profileScarborough, Maine 04074
Global Leader in Cancer
Global Leader in Adenocarcinoma
Conducts research for Ovarian Cancer
Conducts research for Recurrence
Conducts research for Breast Cancer
99 reported clinical trials
15 medical researchers
Summary
Maine Medical Center- Scarborough Campus is a medical facility located in Scarborough, Maine. This center is recognized for care of Cancer, Adenocarcinoma, Ovarian Cancer, Recurrence, Breast Cancer and other specialties. Maine Medical Center- Scarborough Campus is involved with conducting 99 clinical trials across 190 conditions. There are 15 research doctors associated with this hospital, such as Eric C. Larsen, Matthew D. Cheney, Leslie Bradford, MD, and Peter Rubin.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage III
2Adenocarcinoma
Global LeaderStage IV
Stage III
Stage II
Top PIs
Eric C. LarsenMaine Children's Cancer Program7 years of reported clinical research
Studies Lymphoma
Studies Leukemia
24 reported clinical trials
67 drugs studied
Matthew D. CheneyMaine Medical Center- Scarborough Campus2 years of reported clinical research
Studies Cancer
Studies Breast Cancer
20 reported clinical trials
58 drugs studied
Leslie Bradford, MDMaine Medical Center- Scarborough Campus3 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
19 reported clinical trials
49 drugs studied
Peter RubinMaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford5 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
42 drugs studied
Clinical Trials running at Maine Medical Center- Scarborough Campus
Breast Cancer
Prostate Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Ovarian Cancer
Ovarian Carcinoma
Fallopian Tube Cancer
Ovarian Tumors
Small Cell Lung Cancer
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Denosumab to Prevent Breast Cancer in Women With BRCA1 Mutation
for undefined
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.
Recruiting1 award Phase 38 criteria
Online Sexual Health Program
for Breast Cancer Survivors
The goal of this clinical trial is to develop an effective internet-delivered program to help breast cancer survivors manage cancer-related sexual concerns. This study is being done to find out if the study approach is better or worse than the usual approach to helping breast cancer survivors manage cancer-related sexual concerns. The usual approach is defined as care most cancer survivors get for their cancer-related sexual concerns. Participants will complete a questionnaire and if they qualify, they will be assigned to one of sixteen groups of participants. Groups will get access to various kinds of help through an Internet-delivered program called SHINE, which was designed and is run by researchers at the University of Virginia Center for Behavioral Health and Technology. All groups will get access to education about sexual health after cancer: either a standard education website or an enhanced education web program. Groups may also receive up to three additional web programs on: talking to your clinicians about sexual concerns, and/or talking to your partner about sexual concerns, and/or increasing intimacy. Participants are asked to complete the SHINE program within 12 weeks. After participants finish this 12-week period, the study team will ask them to complete a questionnaire to check in with the participant. The participant will be asked one additional time 12 weeks later to complete another questionnaire to see how the participant is doing. A participant will be in the study for 24 weeks.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Maine Medical Center- Scarborough Campus?
Maine Medical Center- Scarborough Campus is a medical facility located in Scarborough, Maine. This center is recognized for care of Cancer, Adenocarcinoma, Ovarian Cancer, Recurrence, Breast Cancer and other specialties. Maine Medical Center- Scarborough Campus is involved with conducting 99 clinical trials across 190 conditions. There are 15 research doctors associated with this hospital, such as Eric C. Larsen, Matthew D. Cheney, Leslie Bradford, MD, and Peter Rubin.